A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)

Nelli Bejanyan, Ramon V. Tiu, Azra Raza, Ania Jankowska, Matt Kalaycio, Anjali Advani, Josephine Chan, Yogen Saunthararajah, Lindsey Mooney, Jaroslaw P. MacIejewski, Mikkael A. Sekeres

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)'. Together they form a unique fingerprint.

Medicine & Life Sciences